Introduction
Agonist-dependent or agonist-biased signaling is a new concept in understanding the signaling of the G protein-coupled receptor (GPCR) (1) . It suggests that GPCR agonists activate the downstream signaling pathways in a selective manner. In agonist-biased signaling, some agonists activate one set of pathways and other agonists activate a different set of pathways. A well studied example is GPCRmediated ERK phosphorylation (2, 3) . Generally, two distinct pathways, the PKC and β-arrestin pathways, mediate ERK phosphorylation in the GPCR system. Although both pathways can be observed with nearly all GPCRs, agonists do have preference. Some agonists can use only the PKC pathway to induce ERK phosphorylation, whereas some other agonists can use only the β-arrestin pathway (3) . ERK phosphorylated via the PKC pathway stays in the cytosol and activates p90 ribosomal S6 kinase, whereas ERK phosphorylated via the β-arrestin pathway translocates into the nucleus and activates Elk1 (4, 5) .
The binding of an agonist to a GPCR leads to receptor phosphorylation, which subsequently increases the affinity of the agonist-receptor complex for the cytosolic protein β-arrestin. Translocation of β-arrestin to the receptor complex disrupts receptor-G protein coupling, ceases G protein-mediated signaling, and initiates β-arrestin-mediated signaling (6) . Because the activation of the PKC pathway requires G protein activation, it has been suggested that the affinity of the agonist-receptor complex for β-arrestin determines the selection between the PKC and β-arrestin pathways (7) . However, this interpretation cannot explain why agonists that normally use the β-arrestin pathway do not use the PKC pathway when β-arrestin is removed (4, 7, 8) . Thus we propose that receptor phosphorylation, rather than increased affinity for β-arrestin after phosphorylation, determines the selection between the PKC and β-arrestin pathways.
To prove this hypothesis, the μ-opioid receptor (OPRM1), of which agonist-dependent signaling has been reported, was used as a model. Unlike agonists such as etorphine, fentanyl, and [D-Ala 2 ,N-Me-Phe 4 ,Gly 5 -ol]-enkephalin (DAMGO), morphine has lower abilities to induce receptor phosphorylation, β-arrestin2 recruitment, and receptor internalization (9) (10) (11) . In addition, morphine uses the PKC pathway to induce ERK phosphorylation, whereas etorphine, fentanyl, and DAMGO utilize the β-arrestin pathway (4) . Agonist-dependent signaling was also observed with the desensitization of intracellular calcium ([Ca 2+ ] i ) release: morphine via the PKC pathway and the other three agonists via the β-arrestin pathway (8, 12) . In addition, chronic morphine treatment decreases dendritic spine density in primary hippocampal cultures (13) . Agonists that initiate high receptor phosphorylation, such as etorphine,fentanyl, and DAMGO, do not decrease spine density (14, 15 Products (Emeryville, CA). The AP conjugated secondary antibodies were from BioRad (Hercules, CA). Gi2 antibodies were generated as described previously (19) .
Intracellular calcium measurement
Intracellular calcium was measured using the FLIPR® calcium assay kit (Molecular Devices Corp.) as described previously (8) PKC subtype activity assay Activity of the PKC subtypes was determined by using the PKC activity assay kit from Cell Signaling as described previously (12) . PKCε, PKRα, or PKCγ was immunoprecipitated from the supernatant from total cell lysate by subtype-specific antibodies and Protein G agarose beads. Reaction solution (Cell Signaling) containing biotin-linked PKC substrate was added to the beads. Reaction lasted 15min at 37ºC with rotation, and was stopped by adding an equal volume of EDTA (50mM, pH 8.0). Then the substrates in supernatant were precipitated with 30µl streptavidin-linked beads. The phosphorylated substrates were identified by specific antibodies and Alexa 488 conjugated goat-anti-rabbit antibody (Invitrogen). The PKC subtype activity was determined by measuring the fluorescence intensity using a α-Fusion plate reader (PerkinElmer Life and Analytical Sciences, Boston, MA).
Lipid raft separation and continuous sucrose gradient
Continuous sucrose gradient was used to separate the microdomains on the cell membrane according to their densities as described previously (20) . Briefly, the samples were placed at the bottom of a 5% to 30% continuous sucrose gradient, which was centrifuged at 32,000 rpm for 16 hrs in a SW41 rotor at 4 o C. Twelve fractions (1ml volume each) were further concentrated to 100 µl with trichloroacetic acid precipitation and analyzed with immunoblotting.
Immunoblotting and immunoprecipitation ERK phosphorylation was determined by immunoblotting (4) . Immunoblotting and immunoprecipitation were performed as reported previously (18) . Immunofluorescence was performed with a BD CARV II™ Confocal Imager (including Leica DMIRE2 fluorescence microscope), Hamamatsu EM-CCD C9100 camera, and IPlab 4.0 (BD Biosciences, San Jose, CA) (16) .
Statistic analysis
Experiments were repeated at least four times, and at least eight individual cells were used for images analyses. The results were analyzed by using the two-tailed student t-test and ANOVA test, except for data depicted in Fig.  1, Fig. 2D -E, and Fig. 7 , which were analyzed by the one-way ANOVA test with the Dunnetttest as a post-hoc test for comparisons. The error bars present the standard derivations and "*" indicates a significant difference between the marked result and the basal or control result (indicated in the legends of the X-axis).
Results

Receptor phosphorylation attenuates PKCε activation
To determine the roles played by receptor phosphorylation in activating the PKC pathway, two cell lines (HEKOPRM1 and HEK3A) and four agonists (morphine, etorphine, fentanyl, and DAMGO) were used. HEK3A cells express a phosphorylation-deficient mutant of OPRM1 with S363A, T370A, and S375A mutations. For consistency, "OPRM1" will be used for wild type OPRM1, "3A" will be used for the phosphorylation deficient mutant, and "receptor" will indicate both the wild type and mutants in this discussion. HEKOPRM1 and HEK3A cells have similar receptor expression levels: 6.3±0.4 and 5.8±0.2 pmol/mg protein. In addition, there is no significant difference between the binding affinities of the agonists for OPRM1 and 3A (21) .
Morphine induces maximum ERK phosphorylation and adenylyl cyclase inhibition at 1μM (20) . Considering the relative affinity of the four agonists for OPRM1 and their abilities to induce maximum ERK phosphorylation and adenylyl cyclase inhibition (4, 22) , DAMGO was used at 1μM, whereas etorphine and fentanyl were used at 10nM, to achieved equivalent concentrations. At these concentrations, the agonists induce ERK phosphorylation and adenylyl cyclase inhibition to similar levels.
Because (Fig. 1B) , confirming the ability of 3A to serve as a phosphorylation deficient mutant. PKC is a large kinase family and is divided into three subfamilies, conventional, atypical, and novel, depending on their activation mechanisms (23). PKCα, PKCγ, and PKCε contribute to morphine-induced tolerance (24) . Thus, the activities of PKCα, PKCγ, and PKCε were determined after agonist treatment. Morphine induced PKCε activation (314±43% of control, n=4) in HEKOPRM1 cells. Fentanyl induced a much lower activation of PKCε (158±21%, n=4). Neither etorphine (103±12%, n=4) nor DAMGO (101±8%, n=4) induced activation of PKCε (Fig. 1C) . In the HEK3A cells, all four agonists activated PKCε (Fig. 1D ). Etorphine and DAMGO induced lower activation of PKCε (228±22% and 207±35% of control, n=4) than did morphine and fentanyl (335±37% and 307±18%, respectively, n=4).
In HEKOPRM1 cells, the intensity of agonist-induced PKCε activation was such that morphine was greater than fentanyl, which was greater than etorphine or DAMGO. Intensity of receptor phosphorylation, on the other hand, was such that etorphine and DAMGO were greater than fentanyl, which was greater than morphine. In HEK3A cells, all four agonists activated PKCε but did not induce receptor phosphorylation. Thus, the ability of the agonists to activate PKCε inversely correlates with their ability to induce receptor phosphorylation. Therefore, it is reasonable to suggest that receptor phosphorylation attenuates PKCε activation.
Receptor phosphorylation attenuates the recruitment of PKCε
After being activated, PKCs translocate from cytosol to the cell membrane (23). Therefore, we measured the translocation of PKCε to the cell membrane to confirm the influence of receptor phosphorylation on PKCε activation. Continuous sucrose gradient was used to separate the microdomains on the cell membrane as described previously (20) . The distribution of lipid raft microdomains was marked by Gαi2 (25) and that of non-raft microdomains was marked by transferrin receptor (26) . The amounts of Gαi2, transferrin receptor, and PKCε peaked at fraction 4, 6, and 12, respectively ( Fig. 2A) . The percentage amounts of target proteins in fractions 3-5 were used to indicate their distribution in the lipid raft microdomains.
In the absence of an agonist, the majority of the receptor was in the lipid raft microdomains in both HEKOPRM1 and HEK3A cells (Fig. 2B  and C) . PKCε was enriched in fractions 11 and 12, suggesting the cytosolic location of PKCε under the control condition. In HEKOPRM1 cells, morphine induced translocation of PKCε from the cytosol to the lipid raft microdomains (Fig. 2B) . Fentanyl also induced translocation, but the percentage of PKCε translocated to fractions 3-5 totalled only 8.1±1% (n=4), which is much less than that (52±12%, n=4) induced by morphine. Etorphine and DAMGO did not affect the location of PKCε [2.7±2% (n=4) and 3.4±2% (n=4), respectively]. In HEK3A cells, all four agonists induced translocation of PKCε: morphine (48±9%, n=4), etorphine (32±6%, n=4), fentanyl (43±9%, n=4), and DAMGO (29±4%, n=4) (Fig. 2C) .
Since PKCε translocated to the lipid raft microdomains after receptor activation, the interaction between the receptor signaling complex and PKCε was monitored by immunoprecipitation. In HEKOPRM1 cells, the interaction between the OPRM1 complex and PKCε was identified only after morphine or fentanyl treatment. The morphine-OPRM1 complex precipitated more PKCε (372±34% of control, n=4) than did the fentanyl-OPRM1 receptor complex (184±17% of control, n=4) (Fig. 2D) . However, all four agonists induced significant recruitment of PKCε to the receptor signaling complex in HEK3A cells (Fig. 2E) .
Blocking receptor phosphorylation switches agonists from the β-arrestin2 pathway to the PKCε pathway
Morphine-induced ERK phosphorylation and receptor desensitization of [Ca 2+ ] i release require PKCε activation, whereas etorphine and DAMGO use the β-arrestin2 pathway to initiate these two signaling events (4, 12) . Since etorphine and DAMGO activated and recruited PKCε in HEK3A cells, whether phosphorylation blockage could switch these agonists from the β-arrestin2 pathway to the PKCε pathway was investigated. To distinguish the signaling mediated by PKCε from that mediated by β-arrestin2, a PKCε-specific inhibitor (PKCεi) was used.
As predicted, PKCεi attenuated ERK phosphorylation induced by morphine in HEKOPRM1 cells, from 237±11% to 115±14% (n=4) of basal level (Fig. 3A) . In addition, PKCεi slightly attenuated fentanyl-induced ERK phosphorylation, but did not affect that induced by either etorphine or DAMGO. In HEK3A cells, all four agonists induced ERK phosphorylation (Fig. 3B) . Because of the low affinity of 3A for β-arrestin2, another pathway is likely involved that mediates ERK phosphorylation, presumably the PKCε pathway. PKCεi reduced the ability of all four agonists to induce ERK phosphorylation in HEK3A cells: morphine from 227±11% to 117±18%; etorphine from 155±14% to 111±8%; fentanyl from 195±13% to 125±11%; DAMGO from 144±8% to 103±9% (n=4) (Fig. 3B) .
Receptor desensitization of [Ca 2+ ] i release also was monitored after agonist treatment to further establish the relationship between receptor phosphorylation and PKCε-related signaling. Since the concentrations of agonists used above induce desensitization quickly, morphine and DAMGO were used at 100nM, and the other two agonists at 1 nM. PKCεi was used to distinguish PKCε-mediated desensitization from β-arrestin2-mediated desensitization. Morphine-induced receptor desensitization was PKCε-mediated in both cell lines (Fig. 4A ). Etorphine and DAMGO induced less desensitization in HEK3A cells than in HEKOPRM1 cells. Desensitization induced by etorphine and DAMGO in HEKOPRM1 cells was not mediated by PKCε, since PKCεi did not affect the desensitization. However, receptor desensitization induced by etorphine and DAMGO in HEK3A cells was PKCε-mediated ( Fig. 4B and D) . Fentanyl functioned as a combination of morphine and etorphine, although more similarly to etorphine (Fig. 4C) . Thus, blocking receptor phosphorylation enables etorphine and DAMGO to use the PKCε pathway, although not as efficiently as morphine.
Attenuation
of PKCε activation is independent of the increased affinity of the receptor complex for β-arrestin2.
Receptor phosphorylation increases the affinity of an agonist-receptor complex for β-arrestin2 (6). However, this increased affinity of an agonist-receptor complex for β-arrestin2 is not the reason why receptor phosphorylation prevents PKCε activation. MEF cells from wild type (WTMEF) and β-arrestin2 -/-(BKOMEF) mice were used. The adenoviruses encoding the wild type OPRM1 (AdOPRM1) and 3A mutant (Ad3A) were used to express the receptor in the MEF cells. In order to compare the results from these two types of MEF cells, the amounts of adenoviruses were titrated precisely to express the receptor at 0.5 pmol/mg. The results obtained in the WTMEF cells infected with AdOPRM1 and Ad3A were similar to those observed in HEKOPRM1 and HEK3A cells. The blockage of receptor phosphorylation increased the ability of etorphine, fentanyl, and DAMGO to use the PKCε-pathway, although less efficiently than morphine (Table 1 ).
In the BKOMEF infected with AdOPRM1, etorphine and DAMGO did not induce ERK phosphorylation or receptor desensitization, indicating they did not activate PKCε pathway (Table 1) . Receptor phosphorylation therefore prevents agonists from using the PKCε pathway directly rather than by increasing the affinity of agonist-receptor for β-arrestin2. In addition, etorphine and DAMGO activated the PKCε pathway in BKOMEF infected with Ad3A as efficiently as morphine. Considering that etorphine and DAMGO activate the PKCε pathway less efficiently than morphine in WTMEF infected with Ad3A, the existence of β-arrestin2 limited the activation of PKCε pathway, presumably through the basal affinity of β-arrestin2 for the non-phosphorylated receptor.
Phosphorylation on Ser 375 is the major inhibitor of PKCε activation
Three residues were mutated in the 3A to prevent receptor phosphorylation. Since Ser 375 has been suggested to be the major site for agonist-induced receptor phosphorylation (8, 21) , the contribution of phosphorylation on these three residues to PKCε activation was investigated. Ser 363 , Thr 370 , and Ser 375 were mutated to Ala individually and stably expressed in HEK293 cells. The activity of PKCε was determined in these cells lines after agonist treatment. Etorphine and DAMGO induced PKCε activation in HEKS363A and HEKT370A cells, but the activation was much less than in HEKS375A cells. Etorphine activated PKCε to 102±14% in HEKOPRM1 cells, while to 136±7%, 152±7%, and 234±22% of basal level in HEKS363A, HEKT370A, and HEKS375A cells, respectively (Fig. 5A) . DAMGO activated PKCε to 108±12%, 127±13%, 153±12%, and 227±9% of basal level in HEKOPRM1, HEKS363A, HEKT370A and HEKS375A cells, respectively. In addition, fentanyl-induced PKCε activation was potentiated much more in HEKS375A than in HEKS363A or HEKT370A cells.
Ser 375 in OPRM1 has been suggested to be the phosphorylation site of G protein-coupled receptor kinase 2 (GRK2) (8, 21) , thus wild type GRK2 and a dominant negative mutant of GRK2 (GRK2-K220R) were over-expressed in HEKOPRM1 cells to modulate the ability of the agonists to induce receptor phosphorylation. As indicated in Fig. 5B , wild type GRK2 overexpression increased the ability of all four agonists to induce receptor phosphorylation, whereas GRK2-K220R over-expression resulted in the opposite effect. The activities of PKCε were measured after over-expression. Morphineinduced activation of PKCε was potentiated by GRK2-K220R, but impaired by GRK2 (Fig. 5C) . Although GRK2 over-expression could not reduced PKCε activity to below basal level, GRK2-K220R over-expression did increase the ability of etorphine, fentanyl, and DAMGO to activate PKCε. Since Ser 375 is the major functional site, an adenovirus expressing a S375A mutant of OPRM1 (AdS375A) was used in further studies.
S375A mutation switches agonists to the PKCε pathway in primary cultures
HEK cells have different characteristics from neuronal cells in which OPRM1 is expressed endogenously. Hence, primary cultures of mouse hippocampal neurons were used to confirm the ability of receptor phosphorylation to impair the activation of the PKCε pathway. As predicted, morphine, but not etorphine or DAMGO, activated PKCε in the primary cultures, whereas fentanyl activated PKCε to a lower level than morphine (Fig. 6A) . When the primary cultures were pretreated with the general opioid receptor antagonist naloxone and the OPRM1 specific antagonist Cys 2 -Tyr 3 -Orn 5 -Pen 7 -amide, PKCε activation was attenuated, indicating that agonist-induced PKCε activation is through OPRM1. In addition, pretreatment with PKC subtype-specific inhibitors demonstrated that PKCε, but not PKCα or PKCγ, is activated by OPRM1 in the primary cultures (Fig. 6B) .
Hippocampal primary cultures from wild type mice and β-arrestin2 -/-mice were prepared as described in Experimental Procedures. AdOPRM1 and AdS375A were used to express exogenous receptors and to determine the effect of phosphorylation blockage on PKCε activation. In both primary cultures, phosphorylation blockage increased the ability of etorphine, DAMGO, and fentanyl to activate PKCε ( Fig.  6C and D) . Therefore, receptor phosphorylation also directly prevented the agonists from using the PKCε pathway in primary cultures. The adenoviruses generated a receptor expression level at about 0.45 pmol/mg protein, which is much higher than the endogenous OPRM1 level (about 0.048 pmol/mg protein) (Fig. 7A) . Infection efficiency is indicated in Fig.  7B and C, and the percentage of the infected primary cultures (HA-positive) in DAPI positive cells was close to 90%. Therefore, after adenovirus infection, the primary cultures express much more exogenous receptor than endogenous OPRM1, resulting in for the ability to determine agonist-dependent signaling in primary cultures.
S375A mutation reversed the effects of agonists on dendritic spine stability
It has been reported that agonist-dependent activation of ERK resulted in differential regulation of miR-190, NeuroD, and dendritic spines stability (16) (17) (18) . Primary cultures from wild type mice were infected with AdOPRM1 or AdS375A for three days, and the dendritic spine stability was monitored during the next three days with agonist incubation. In addition, the level of miR-190 and NeuroD mRNA was quantified in the infected primary cultures.
In AdOPRM1 infected primary cultures, etorphine, fentanyl, and DAMGO induced decreases in miR-190 expression (54±16%, 61±12%, and 51±9%, respectively, n=4) (Fig.  8A) . However, in AdS375A-infected primary cultures, the effects of these three agonists on miR-190 were attenuated. In addition, etorphine, fentanyl, and DAMGO increased NeuroD mRNA level in AdOPRM1-infected, but not in AdS375A-infected, primary cultures.
In AdOPRM1-infected primary cultures, similar observations were obtained as reported previously. A three-day morphine treatment decreased the volume of dendritic spines by 40±12%, where as treatments with etorphine, fentanyl, and DAMGO did not decrease spine volume (Fig. 8C and D) .
When used to treat the AdS375A-infected primary cultures, all four agonists significantly decreased spine volume during the three-day treatments. Morphine, etorphine, fentanyl, and DAMGO decreased spine volume by 47±12%, 24±7%, 23±11%, and 27±9% from that on Day 0, respectively ( Fig. 8C and D) . Thus, phosphorylation blockage can regulate the effects of agonists, such as etorphine, fentanyl, and DAMGO, on dendritic spine stability.
Discussion
Four agonists (morphine, fentanyl, etorphine and DAMGO) and two signaling events (ERK phosphorylation and desensitization) were examined in the current studies. In summary, three types of agonists were represented. Morphine activated the PKCε pathway and used only the PKCε pathway for ERK phosphorylation. Etorphine and DMAGO did not activate the PKCε pathway and used only the β-arrestin2 pathway for ERK phosphorylation. Fentanyl acted more like etorphine and DAMGO, but it could activate the PKCε pathway. Thus it represented agonists that can use both pathways for ERK phosphorylation.
Etorphine and DAMGO used the β-arrestin2 pathway for signaling in the presence of both receptor phosphorylation and β-arrestin2. If β-arrestin2 was removed from the system, no activation of ERK was observed. In contrast, if receptor phosphorylation was blocked, the two agonists utilize the PKCε pathway for signaling. Thus, receptor phosphorylation, rather than the increased affinity of the receptor complex for β-arrestin2, attenuates activation of the PKCε pathway. These observations were consistent with the report that phosphorylation of the δ-opioid receptor regulates agonist-dependent signaling (27) . However, the basal affinity between a non-phosphorylated receptor and β-arrestin2 should still limit activation of the PKCε pathway. Morphine induces little receptor phosphorylation and no receptor internalization under normal conditions (9), but over-expression of β-arrestin2 enables morphine to induce significant receptor internalization (28) . In addition, morphine induces significant receptor internalization in striatal neurons, but not in hippocampal neurons, probably due to the differential amounts and basal activities of β-arrestin in these systems (29) . This hypothesis about the basal affinity was also confirmed in the current study. Blocking receptor phosphorylation made etorphine and DAMGO utilize the PKCε pathway, but not as efficiently as morphine. Removing β-arrestin2 additionally enabled etorphine and DAMGO to activate the PKCε pathway to levels similar to that induced by morphine. Therefore, although not the major blocker of PKCε activation, the existence of β-arrestin2 and its affinity for non-phosphorylated receptor also prevents agonists from using the PKCε pathway.
GRK2 over-expression increased the ability of morphine to induce receptor phosphorylation, but decreased morphine's ability to use the PKCε pathway (Fig. 5B and C) . These observations are consistent with the fact that β-arrestin2 over-expression makes morphine switch from the PKC pathway to the β-arrestin2 pathway (4, 8) . These results also provide a possible mechanism for morphine to use the β-arrestin pathway. In addition, the agonists switching from one pathway to another provides a useful tool in controlling the downstream responses to the agonists. On the one hand, the most critical regions on GPCRs for G protein coupling are the second intracellular loop (IL), the N-terminus, and the C-terminus of IL3 (30). On the other hand, in addition to the C-terminus facilitating the binding of β-arrestin by mediating phosphorylation (31) , the IL2, the Nterminus, and the C-terminus of the IL3 are also essential for the binding of β-arrestin (32) (33) (34) (35) (36) . Due to this overlap of binding sites, receptor phosphorylation can be suggested as regulating the competition between G proteins and β-arrestin for the binding site on GPCRs (7) .
Although the inhibitory effects of receptor phosphorylation on PKCε activation were demonstrated in the current studies, the detailed mechanism has not been elucidated completely. One possible mechanism is that conformational changes of the receptor during phosphorylation prevent activation of PKCε. The different affinities between phosphorylated and nonphosphorylated receptors for β-arrestin support the existence of conformational differences. In addition, GRK2 is recruited to the cell membrane and binds with the receptor after activation by free Gγ subunits (37) (38) (39) . The binding of GRK2 to the receptor signaling complex also may be the reason that activation of PKCε is prevented.
As reported previously, the different abilities of morphine and fentanyl to affect miR-190, NeuroD, and subsequent dendritic spine stability are due to the different pathways used by them to induce ERK phosphorylation (18) 
